These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 17182597)
1. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597 [TBL] [Abstract][Full Text] [Related]
2. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Mkrtichyan M; Ghochikyan A; Loukinov D; Davtyan H; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG Gene Ther; 2008 Jan; 15(1):61-4. PubMed ID: 17972923 [TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. Loukinov D; Ghochikyan A; Mkrtichyan M; Ichim TE; Lobanenkov VV; Cribbs DH; Agadjanyan MG J Cell Biochem; 2006 Aug; 98(5):1037-43. PubMed ID: 16741971 [TBL] [Abstract][Full Text] [Related]
4. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917 [TBL] [Abstract][Full Text] [Related]
5. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128 [TBL] [Abstract][Full Text] [Related]
6. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Okada H; Attanucci J; Giezeman-Smits KM; Brissette-Storkus C; Fellows WK; Gambotto A; Pollack LF; Pogue-Geile K; Lotze MT; Bozik ME; Chambers WH Cancer Res; 2001 Mar; 61(6):2625-31. PubMed ID: 11289140 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Marshall DJ; Rudnick KA; McCarthy SG; Mateo LR; Harris MC; McCauley C; Snyder LA Vaccine; 2006 Jan; 24(3):244-53. PubMed ID: 16135392 [TBL] [Abstract][Full Text] [Related]
8. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
9. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models. Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383 [TBL] [Abstract][Full Text] [Related]
10. Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. Mkrtichyan M; Ghochikyan A; Davtyan H; Movsesyan N; Loukinov D; Lobanenkov V; Cribbs DH; Laust AK; Nelson EL; Agadjanyan MG Cell Immunol; 2011; 270(2):188-97. PubMed ID: 21641588 [TBL] [Abstract][Full Text] [Related]
11. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice. Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167 [TBL] [Abstract][Full Text] [Related]
12. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine. Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512 [TBL] [Abstract][Full Text] [Related]
13. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent. Wild J; Grusby MJ; Schirmbeck R; Reimann J J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922 [TBL] [Abstract][Full Text] [Related]
14. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. Ni J; Schirrmacher V; Fournier P Vaccine; 2010 Oct; 28(42):6891-900. PubMed ID: 20709006 [TBL] [Abstract][Full Text] [Related]
15. Induction by DNA immunization of a protective antitumor cytotoxic T lymphocyte response against a minimal-epitope-expressing tumor. Iwasaki A; Barber BH Cancer Immunol Immunother; 1998 Jan; 45(5):273-9. PubMed ID: 9439651 [TBL] [Abstract][Full Text] [Related]
16. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222 [TBL] [Abstract][Full Text] [Related]
17. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. Rice J; Buchan S; Stevenson FK J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189 [TBL] [Abstract][Full Text] [Related]
18. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Tian S; Liu Z; Donahue C; Falo LD; You Z Mol Ther; 2012 Feb; 20(2):432-42. PubMed ID: 21934655 [TBL] [Abstract][Full Text] [Related]
19. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943 [TBL] [Abstract][Full Text] [Related]
20. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]